BioSpace News Archive

Ongoing Phase 1/2 Study Continues to Demonstrate High Rates of Response to a Single Infusion of KTE-X19 in a Patient Population with Limited Treatment Options

Chugai Pharmaceutical Co., Ltd. announced that the primary analysis of the phase III HAVEN 2 study (NCT02795767), evaluating hemophilia A treatment HEMLIBRA® in children with hemophilia A with factor VIII inhibitors, was reported in an Oral Presentation at the 60th American Society of Hematology (ASH) Annual Meeting held in San Diego, USA from December 1 to 4 2018.

Mitsubishi Electric Corporation and the University of Tokyo announced today what they believe to be an all-new mechanism for enhancing the reliability of silicon carbide (SiC) power semiconductor devices in power electronics systems.

-Data Presented in Oral Session with Simultaneous Publication in The Lancet-

Swedish Orphan Biovitrum AB (publ) (Sobi™) and Novimmune SA are presenting data from the pivotal phase 2/3 clinical study of emapalumab-lzsg in primary haemophagocytic lymphohistiocytosis (HLH) as part of the late-breaking abstract session at the 60th Annual Meeting of the American Society of Hematology (ASH), taking place 1-4 December 2018, in San Diego.

Formal agreement closure officially joins fresh food-focused GetGo and Ricker’s brands

Plan has sufficient assets to satisfy all transaction obligations; no Company cash contribution expected

Home telemedicine programs for heart failure are effective at preventing death for at least six months after hospitalization, but generally lose any benefit after one year, according to a meta-analysis of clinical trials published today and announced tomorrow at a briefing.

DionyMed Brands Inc. is providing an operational update following the commencement of trading of the Company’s shares on the Canadian Securities Exchange on November 28, 2018.

Varian today announced that its Board of Directors has scheduled the 2019 Annual Meeting of Stockholders for February 14, 2019 with a record date of December 17, 2018.